A Corpus-based Critical Discourse Analysis of the Reports on China's Double Reduction in Four Mainstream Media
International Journal of Education and Humanities · 26.07.2022 · 3 (3) · 17-19
DOI: 10.54097/ijeh.v3i3.1003 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Education and Humanities, online erschienen am 26.07.2022. Verfasst von Tianbo Yu und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
“Double Reduction Policies”, released by Chinese General Office of the State Council in July 2021, generally refers to the alleviation of students’ burden from heavy homework and off-campus training. The reports from BBC News, the Washington Post, China Daily and Bloomberg on the Double Reduction Policies deserve the attention and research. However, few studies are conducted from the perspective of critical discourse research with in-depth and comprehensive study on the event. Therefore, based on the self-built corpus, this paper analyses the statistics and materials in terms of language features, exploring the difference and attitudes from mainstream media.
Zitieren
APA
Yu, T., & Wang, Z. (2022). A Corpus-based Critical Discourse Analysis of the Reports on China's Double Reduction in Four Mainstream Media. International Journal of Education and Humanities, 3(3), 17-19. https://doi.org/10.54097/ijeh.v3i3.1003
Vancouver
Yu T, Wang Z. A Corpus-based Critical Discourse Analysis of the Reports on China's Double Reduction in Four Mainstream Media. International Journal of Education and Humanities. 2022;3(3):17-19. doi:10.54097/ijeh.v3i3.1003
BibTeX
@article{Yu2022,
author = {Yu, Tianbo and Wang, Zichen},
title = {A Corpus-based Critical Discourse Analysis of the Reports on China's Double Reduction in Four Mainstream Media},
journal = {International Journal of Education and Humanities},
year = {2022},
volume = {3},
number = {3},
pages = {17--19},
doi = {10.54097/ijeh.v3i3.1003}
}
EUVIMED